177 related articles for article (PubMed ID: 24715663)
1. Transdermal opioids for cancer pain control in patients with renal impairment.
Melilli G; Samolsky Dekel BG; Frenquelli C; Mellone R; Pannuti F
J Opioid Manag; 2014; 10(2):85-93. PubMed ID: 24715663
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
5. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Mitra F; Chowdhury S; Shelley M; Williams G
Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
[TBL] [Abstract][Full Text] [Related]
6. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F
Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716
[TBL] [Abstract][Full Text] [Related]
7. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
8. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
Tschirner M; Ritzdorf I; Brünjes R
MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
[TBL] [Abstract][Full Text] [Related]
9. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
[TBL] [Abstract][Full Text] [Related]
10. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
Kress HG
Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
[TBL] [Abstract][Full Text] [Related]
11. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
[TBL] [Abstract][Full Text] [Related]
12. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
Canneti A; Luzi M; Di Marco P; Cannata F; Pasqualitto F; Spinoglio A; Reale C
Minerva Anestesiol; 2013 Aug; 79(8):871-83. PubMed ID: 23558760
[TBL] [Abstract][Full Text] [Related]
14. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
15. Transdermal opioids for cancer pain.
Cachia E; Ahmedzai SH
Curr Opin Support Palliat Care; 2011 Mar; 5(1):15-9. PubMed ID: 21325999
[TBL] [Abstract][Full Text] [Related]
16. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
Barutell C; Camba A; González-Escalada JR; Rodríguez M;
Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
[TBL] [Abstract][Full Text] [Related]
17. Transdermal buprenorphine for postoperative pain control in gynecological surgery: a prospective randomized study.
Setti T; Sanfilippo F; Leykin Y
Curr Med Res Opin; 2012 Oct; 28(10):1597-608. PubMed ID: 22876835
[TBL] [Abstract][Full Text] [Related]
18. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
Sittl R; Nuijten M; Poulsen Nautrup B
Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
[TBL] [Abstract][Full Text] [Related]
19. Transdermal opioids for cancer pain.
Skaer TL
Health Qual Life Outcomes; 2006 Mar; 4():24. PubMed ID: 16573839
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]